{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:58Z","timestamp":1787028778425,"version":"build-2736575974"},"reference-count":166,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Atherosclerosis is a significant health concern with a growing incidence worldwide. It is directly linked to an increased cardiovascular risk and to major adverse cardiovascular events, such as acute coronary syndromes. In this review, we try to assess the potential diagnostic role of biomarkers in the early identification of patients susceptible to the development of atherosclerosis and other adverse cardiovascular events. We have collected publications concerning already established parameters, such as low-density lipoprotein cholesterol (LDL-C), as well as newer markers, e.g., apolipoprotein B (apoB) and the ratio between apoB and apoA. Additionally, given the inflammatory nature of the development of atherosclerosis, high-sensitivity c-reactive protein (hs-CRP) or interleukin-6 (IL-6) are also discussed. Additionally, newer publications on other emerging components linked to atherosclerosis were considered in the context of patient evaluation. Apart from the already in-use markers (e.g., LDL-C), emerging research highlights the potential of newer molecules in optimizing the diagnosis of atherosclerotic disease in earlier stages. After further studies, they might be fully implemented in the screening protocols.<\/jats:p>","DOI":"10.3390\/life13081639","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T01:56:16Z","timestamp":1690509376000},"page":"1639","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment"],"prefix":"10.3390","volume":"13","author":[{"given":"Raul-Alexandru","family":"Jigoranu","sequence":"first","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Cardiology, \u201dSt. Spiridon\u201d Emergency County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Roca","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8544-9904","authenticated-orcid":false,"given":"Alexandru-Dan","family":"Costache","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Mitu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Cardiology, \u201dSt. Spiridon\u201d Emergency County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-4562","authenticated-orcid":false,"given":"Alexandru-Florinel","family":"Oancea","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Cardiology, \u201dSt. Spiridon\u201d Emergency County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2610-6482","authenticated-orcid":false,"given":"Radu-Stefan","family":"Miftode","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Cardiology, \u201dSt. Spiridon\u201d Emergency County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai \u0218tefan Cristian","family":"Haba","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Cardiology, \u201dSt. Spiridon\u201d Emergency County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eosefina Gina","family":"Botnariu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Diabetes, Nutrition and Metabolic Diseases, \u201dSt. Spiridon\u201d Emergency County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-9696","authenticated-orcid":false,"given":"Alexandra","family":"Ma\u0219taleru","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-6573","authenticated-orcid":false,"given":"Radu-Sebastian","family":"Gavril","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan-Andrei","family":"Trandabat","sequence":"additional","affiliation":[{"name":"Department of Surgery II, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Orthopedics and Trauma, Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina Ioana","family":"Chirica","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-3521","authenticated-orcid":false,"given":"Raluca Maria","family":"Haba","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Magdalena","family":"Leon","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina-Iuliana","family":"Costache","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Department of Cardiology, \u201dSt. Spiridon\u201d Emergency County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-9327","authenticated-orcid":false,"given":"Florin","family":"Mitu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties I, Faculty of Medicine, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"},{"name":"Romanian Academy of Medical Sciences, 030167 Bucharest, Romania"},{"name":"Romanian Academy of Scientists, 050045 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.arcmed.2015.06.006","article-title":"Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease","volume":"46","author":"Barquera","year":"2015","journal-title":"Arch. Med. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: Epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41569-021-00607-3","article-title":"Epidemiology of cardiovascular disease in Europe","volume":"19","author":"Townsend","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e009778","DOI":"10.1161\/JAHA.118.009778","article-title":"Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life","volume":"7","author":"Robinson","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/eurheartj\/ehv236","article-title":"Novel methodologies for biomarker discovery in atherosclerosis","volume":"36","author":"Hoefer","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9.23.1","DOI":"10.1002\/cpph.19","article-title":"Biomarkers-A General Review","volume":"76","author":"Aronson","year":"2017","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_8","unstructured":"Willis, M.S., Homeister, J.W., and Stone, J.R. (2014). Cellular and Molecular Pathobiology of Cardiovascular Disease, Elsevier."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1586\/erc.10.28","article-title":"Shear stress and plaque development","volume":"8","author":"Dhawan","year":"2010","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41569-019-0239-5","article-title":"Endothelial responses to shear stress in atherosclerosis: A novel role for developmental genes","volume":"17","author":"Souilhol","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_11","first-page":"1081881","article-title":"Vascular smooth muscle cells in intimal hyperplasia, an update","volume":"13","author":"Bechelli","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.carpath.2012.06.006","article-title":"Vascular Endothelium, Hemodynamics, and the Pathobiology of Atherosclerosis","volume":"22","author":"Gimbrone","year":"2013","journal-title":"Cardiovasc. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and Inflammation in Atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., Tang, D., and Chen, R. (2018). Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules, 8.","DOI":"10.3390\/biom8030080"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4354786","DOI":"10.1155\/2019\/4354786","article-title":"Vascular Macrophages in Atherosclerosis","volume":"2019","author":"Xu","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/cvr\/cvz338","article-title":"Lipoprotein receptor signalling in atherosclerosis","volume":"116","author":"Mineo","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOL.0000000000000302","article-title":"Atherosclerosis: The interplay between lipids and immune cells","volume":"27","author":"Schaftenaar","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","article-title":"How the immune system shapes atherosclerosis: Roles of innate and adaptive immunity","volume":"22","author":"Roy","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"992653","DOI":"10.3389\/fcvm.2022.992653","article-title":"CD4+ T-lymphocytes exhibit biphasic kinetics post-myocardial infarction","volume":"9","author":"Kumar","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacbts.2022.05.005","article-title":"TNFR1 Contributes to Activation-Induced Cell Death of Pathological CD4+ T Lymphocytes During Ischemic Heart Failure","volume":"7","author":"Kumar","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI200420479","article-title":"IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis","volume":"114","author":"Binder","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","article-title":"Atherosclerosis. the road ahead","volume":"104","author":"Glass","year":"2001","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Summerhill, V.I., Grechko, A.V., Yet, S.F., Sobenin, I.A., and Orekhov, A.N. (2019). The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143561"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e002941","DOI":"10.1161\/JAHA.115.002941","article-title":"Relation Between Adolescent Cardiovascular Risk Factors and Carotid Intima-Media Echogenicity in Healthy Young Adults: The Atherosclerosis Risk in Young Adults (ARYA) Study","volume":"5","author":"Eikendal","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_25","unstructured":"Venugopal, S.K., and Jialal, I. (2019). StatPearls, StatPearls Publishing."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.10.013","article-title":"The pathology of atherosclerosis: Plaque development and plaque responses to medical treatment","volume":"122","author":"Insull","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jebari-Benslaiman, S., Galicia-Garc\u00eda, U., Larrea-Sebal, A., Olaetxea, J.R., Alloza, I., Vandenbroeck, K., Benito-Vicente, A., and Mart\u00edn, C. (2022). Pathophysiology of Atherosclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063346"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s42255-020-00338-8","article-title":"Multiple cell types contribute to the atherosclerotic lesion fibrous cap by PDGFR\u03b2 and bioenergetic mechanisms","volume":"3","author":"Newman","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_29","unstructured":"Gopalan, C., and Kirk, E. (2022). Biology of Cardiovascular and Metabolic Diseases, Academic Press."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.mpdhp.2017.11.009","article-title":"Pathogenesis of atherosclerosis","volume":"23","author":"Wang","year":"2017","journal-title":"Diagn. Histopathol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Aprotosoaie, A.C., Costache, A.D., and Costache, I.I. (2022). Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040722"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1388-1981(00)00123-2","article-title":"Structure of low density lipoprotein (LDL) particles: Basis for understanding molecular changes in modified LDL","volume":"1488","author":"Hevonoja","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101342","DOI":"10.1016\/j.cpcardiol.2022.101342","article-title":"Lipid Lowering Therapy: An Era Beyond Statins","volume":"47","author":"Bukhari","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1021\/bi00355a016","article-title":"Packing of cholesterol molecules in human low-density lipoprotein","volume":"25","author":"Phillips","year":"1986","journal-title":"Biochemistry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1194\/jlr.M009258","article-title":"Proteomic analysis of electronegative low-density lipoprotein","volume":"51","author":"Bancells","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_36","unstructured":"Devaraj, S., Semaan, J.R., and Jialal, I. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00249-008-0368-y","article-title":"Molecular structure of low density lipoprotein: Current status and future challenges","volume":"38","author":"Prassl","year":"2009","journal-title":"Eur. Biophys. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/HCO.0000000000000740","article-title":"Measuring LDL-cholesterol: What is the best way to do it","volume":"35","author":"Wolska","year":"2020","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13545","DOI":"10.1038\/s41598-021-92625-x","article-title":"Comparison of the effectiveness of Martin\u2019s equation, Friedewald\u2019s equation, and a Novel equation in low-density lipoprotein cholesterol estimation","volume":"11","author":"Song","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin. Lab. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0009-8981(93)90027-2","article-title":"LDL sialic acid content in patients with coronary artery disease","volume":"221","author":"Ruelland","year":"1993","journal-title":"Clin. Chim. Acta"},{"key":"ref_42","first-page":"155","article-title":"Characterization of desialylated low-density lipoproteins which cause intracellular lipid accumulation","volume":"14","author":"Tertov","year":"1992","journal-title":"Int. J. Tissue React."},{"key":"ref_43","first-page":"665","article-title":"Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization","volume":"67","author":"Tertov","year":"1992","journal-title":"Lab. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1273042","DOI":"10.1155\/2017\/1273042","article-title":"Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases","volume":"2017","author":"Ivanova","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.crvasa.2016.10.003","article-title":"Circulating desialylated low density lipoprotein","volume":"59","author":"Orekhov","year":"2016","journal-title":"Cor et Vasa"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2008.04.036","article-title":"Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro","volume":"202","author":"Younis","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MOL.0b013e328348a43f","article-title":"Susceptibility of LDL and its subfractions to glycation","volume":"22","author":"Soran","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1210\/jcem.87.5.8466","article-title":"Glycated low density lipoproteins modify platelet properties: A compositional and functional study","volume":"87","author":"Ferretti","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_49","first-page":"707","article-title":"Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes","volume":"31","author":"Cohen","year":"1993","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"ref_50","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"Steinberg","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.hlc.2018.06.1057","article-title":"Markers of Atherosclerosis: Part 1\u2014Serological Markers","volume":"28","author":"Tibaut","year":"2019","journal-title":"Heart Lung Circ."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"714653","DOI":"10.1155\/2013\/714653","article-title":"The role of oxidized low-density lipoproteins in atherosclerosis: The myths and the facts","volume":"2013","author":"Maiolino","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1172\/JCI119528","article-title":"Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I\/II gene","volume":"100","author":"Ling","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MOL.0b013e32832fa58d","article-title":"Circulating oxidized LDL: A biomarker and a pathogenic factor","volume":"20","author":"Ishigaki","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.cjca.2017.07.015","article-title":"Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies","volume":"33","author":"Gao","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"110040","DOI":"10.1016\/j.diabres.2022.110040","article-title":"Association between circulating oxidized OxLDL\/LDL-C ratio and the severity of coronary atherosclerosis, along with other emerging biomarkers of cardiovascular disease in patients with type 2 diabetes","volume":"191","author":"Xu","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2174\/1381612829666230417100144","article-title":"Potential Biomarkers and Therapeutic Targets: Inflammation and Oxidative Stress in Left Carotid Artery Stenosis with Coronary Artery Disease","volume":"29","author":"Li","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/M15-2994","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review","volume":"164","author":"Navarese","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial","volume":"327","author":"Ueki","year":"2022","journal-title":"JAMA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e025858","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12918","DOI":"10.1016\/S0021-9258(18)69248-8","article-title":"The complete cDNA and amino acid sequence of human apolipoprotein B-100","volume":"261","author":"Chen","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pathol.2018.11.006","article-title":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment","volume":"51","author":"Carr","year":"2019","journal-title":"Pathology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0889-8529(05)70023-2","article-title":"Lipoprotein physiology","volume":"27","author":"Ginsberg","year":"1998","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2796.2005.01556.x","article-title":"Apolipoprotein B: A clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis","volume":"258","author":"Olofsson","year":"2005","journal-title":"J. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/ATVBAHA.111.241471","article-title":"Intracellular trafficking and secretion of VLDL","volume":"32","author":"Tiwari","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.ATV.14.10.1674","article-title":"apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE","volume":"14","author":"Segrest","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1021\/acs.biochem.6b01174","article-title":"Relationship between Amphipathic \u03b2 Structures in the \u03b21 Domain of Apolipoprotein B and the Properties of the Secreted Lipoprotein Particles in McA-RH7777 Cells","volume":"56","author":"Manchekar","year":"2017","journal-title":"Biochemistry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"44702","DOI":"10.1074\/jbc.M307562200","article-title":"Identification of the lipoprotein initiating domain of apolipoprotein B","volume":"278","author":"Shelness","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/323738a0","article-title":"Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100","volume":"323","author":"Yang","year":"1986","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L.J., De Leon, J., Glass, A.D., and Reiss, A.B. (2021). Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites, 11.","DOI":"10.3390\/metabo11100690"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaa077","article-title":"2019 ESC\/EAS Guidelines for management of dyslipidaemia: Strengths and limitations","volume":"7","author":"Zeitouni","year":"2021","journal-title":"Eur. Heart. J. Cardiovasc. Pharmacother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","article-title":"Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study","volume":"25","author":"Cantin","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.numecd.2021.01.013","article-title":"LDL\/apo B ratio predict coronary heart disease in Type 2 diabetes independent of ASCVD risk score: A case-cohort study","volume":"31","author":"Rabizadeh","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e32596","DOI":"10.1097\/MD.0000000000032596","article-title":"The LDL-C\/Apo B predicts coronary atherosclerotic heart disease in non-diabetic patients without high LDL-C","volume":"102","author":"Jung","year":"2023","journal-title":"Medicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-19-1592-5_1","article-title":"HDL Structure","volume":"1377","author":"Deng","year":"2022","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11883-006-0033-9","article-title":"Apolipoprotein A-I and risk for cardiovascular diseases","volume":"8","author":"Khuseyinova","year":"2006","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00059-014-4147-5","article-title":"Apolipoprotein B\/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients","volume":"40","author":"Liting","year":"2015","journal-title":"Herz"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals with and without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","article-title":"Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters","volume":"70","author":"Gangestad","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"106806","DOI":"10.1016\/j.vph.2020.106806","article-title":"Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome","volume":"135","author":"Gager","year":"2020","journal-title":"Vasc. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Danesh, J., Kaptoge, S., Mann, A.G., Sarwar, N., Wood, A., Angleman, S.B., Wensley, F., Higgins, J.P., Lennon, L., and Eiriksdottir, G. (2008). Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Med., 5.","DOI":"10.1371\/journal.pmed.0050078"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"115327","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors","volume":"28","author":"Kaur","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1084\/jem.165.3.914","article-title":"Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma\/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor","volume":"165","author":"Opdenakker","year":"1987","journal-title":"J. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0014-5793(89)80805-1","article-title":"Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas","volume":"250","author":"Miki","year":"1989","journal-title":"FEBS Lett."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1073\/pnas.87.11.4068","article-title":"AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6","volume":"87","author":"Miles","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.RES.0000115557.25127.8D","article-title":"Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor","volume":"94","author":"Wassmann","year":"2004","journal-title":"Circ. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1161\/ATVBAHA.107.153080","article-title":"IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy","volume":"27","author":"Schrader","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2353\/ajpath.2007.061078","article-title":"Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo","volume":"171","author":"Coles","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1161\/01.CIR.0000148135.08582.97","article-title":"Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis","volume":"110","author":"Schieffer","year":"2004","journal-title":"Circulation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH09-05-0297","article-title":"How much is too much? Interleukin-6 and its signalling in atherosclerosis","volume":"102","author":"Schuett","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1210\/me.2005-0490","article-title":"Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle","volume":"20","author":"Bouzakri","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"155742","DOI":"10.1016\/j.cyto.2021.155742","article-title":"Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints","volume":"149","author":"Jarlborg","year":"2022","journal-title":"Cytokine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9150(99)00463-3","article-title":"Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link","volume":"148","author":"Yudkin","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e1002","DOI":"10.1212\/WNL.0000000000013274","article-title":"Circulating Interleukin-6 Levels and Incident Ischemic Stroke: A Systematic Review and Meta-analysis of Prospective Studies","volume":"98","author":"Papadopoulos","year":"2022","journal-title":"Neurology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/08820139.2018.1480034","article-title":"Interleukin-6 as a Predictor of the Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Epidemiological Studies","volume":"47","author":"Zhang","year":"2018","journal-title":"Immunol. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.104.513085","article-title":"C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study","volume":"112","author":"Tzoulaki","year":"2005","journal-title":"Circulation"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.atherosclerosis.2008.07.031","article-title":"Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)","volume":"203","author":"Saremi","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5152\/EurJTher.2017.01007","article-title":"Relation of Interleukin-6 Level with Coronary Artery Disease Severity in Patients Undergoing Coronary Angiography","volume":"23","author":"Gerin","year":"2020","journal-title":"Eur. J. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jcmg.2022.03.016","article-title":"Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients with Chest Pain: The PROMISE Trial Results","volume":"15","author":"Ferencik","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13098-022-00891-0","article-title":"Increased serum IL-6 is predictive of long-term cardiovascular events in high-risk patients submitted to coronary angiography: An observational study","volume":"14","author":"Mossmann","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10554-017-1098-y","article-title":"Association between interleukin-6 and the risk of cardiac events measured by coronary computed tomography angiography","volume":"33","author":"Zhao","year":"2017","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11010-017-3054-5","article-title":"Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography","volume":"435","author":"Tajfard","year":"2017","journal-title":"Mol. Cell Biochem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: Analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, andomized, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: Will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5603\/AA.2020.0005","article-title":"Selected Biomarkers of Atherosclerosis\u2014Clinical Aspects","volume":"26","author":"Surma","year":"2020","journal-title":"Acta Angiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ijo.2012.88","article-title":"Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malm\u00f6 Diet and Cancer Study cardiovascular cohort","volume":"37","author":"Bankir","year":"2013","journal-title":"Int. J. Obes."},{"key":"ref_121","first-page":"341","article-title":"Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the Individual stress level","volume":"29","author":"Katan","year":"2008","journal-title":"Neuroendocrinol. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ahj.2014.11.020","article-title":"Copeptin is an independent predictor of diabetic heart disease and death","volume":"169","author":"Hedblad","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/pedi.12909","article-title":"Elevated copeptin, arterial stiffness, and elevated albumin excretion in adolescents with type 1 diabetes","volume":"20","author":"Wiromrat","year":"2019","journal-title":"Pediatr. Diabetes"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/heartjnl-2015-308183","article-title":"Copeptin predicts coronary artery disease cardiovascular and total mortality","volume":"102","author":"Tasevska","year":"2016","journal-title":"Heart"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cca.2021.07.024","article-title":"Midkine: A multifaceted driver of atherosclerosis","volume":"521","author":"Zhang","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"10345","DOI":"10.1038\/s41598-020-67217-w","article-title":"Growth Factor Midkine Aggravates Pulmonary Arterial Hypertension via Surface Nucleolin","volume":"10","author":"Kinoshita","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cardfail.2009.12.014","article-title":"Serum midkine as a predictor of cardiac events in patients with chronic heart failure","volume":"16","author":"Kitahara","year":"2010","journal-title":"J. Card. Fail."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1253\/circj.CJ-17-0043","article-title":"Midkine Promotes Atherosclerotic Plaque Formation through Its Pro-Inflammatory, Angiogenic and Anti-Apoptotic Functions in Apolipoprotein E-Knockout Mice","volume":"82","author":"Takemoto","year":"2017","journal-title":"Circ. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e000955","DOI":"10.1136\/openhrt-2018-000955","article-title":"Performance of a clinical\/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus","volume":"6","author":"McCarthy","year":"2019","journal-title":"Open Heart"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2016.12.021","article-title":"A Clinical and Biomarker Scoring System to Predict the Presence of Obstructive Coronary Artery Disease","volume":"69","author":"Ibrahim","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/01.ATV.20.7.1716","article-title":"Oxidation of LDL by myeloperoxidase and reactive nitrogen species: Reaction pathways and antioxidant protection","volume":"20","author":"Carr","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"107711","DOI":"10.1016\/j.pharmthera.2020.107711","article-title":"Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease","volume":"221","author":"Maiocchi","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00508-019-01602-y","article-title":"Linking myeloperoxidase with subclinical atherosclerosis in adults with metabolic syndrome","volume":"132","author":"Iana","year":"2020","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2007.03.033","article-title":"Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The EPIC-Norfolk Prospective Population Study","volume":"50","author":"Meuwese","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fphys.2018.01712","article-title":"GDF15 and Growth Control","volume":"9","author":"Emmerson","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","article-title":"The MIC-1\/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases","volume":"28","author":"Tsai","year":"2018","journal-title":"Cell Metab."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Miftode, R.S., Constantinescu, D., Cianga, C.M., Petris, A.O., Costache, I.I., Mitu, O., Miftode, I.L., Mitu, I., Timpau, A.S., and Duca, S.T. (2022). A Rising Star of the Multimarker Panel: Growth Differentiation Factor-15 Levels Are an Independent Predictor of Mortality in Acute Heart Failure Patients Admitted to an Emergency Clinical Hospital from Eastern Europe. Life, 12.","DOI":"10.3390\/life12121948"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00392-019-01554-3","article-title":"Circulatory factors associated with function and prognosis in patients with severe heart failure","volume":"109","author":"Rullman","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e012826","DOI":"10.1161\/JAHA.119.012826","article-title":"Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease","volume":"8","author":"Wang","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.106.650846","article-title":"Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome","volume":"115","author":"Wollert","year":"2007","journal-title":"Circulation"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/eurheartj\/ehm465","article-title":"Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction","volume":"28","author":"Kempf","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/ATVBAHA.110.213512","article-title":"Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: Observations from PROVE IT-TIMI 22","volume":"31","author":"Bonaca","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.jacc.2017.03.580","article-title":"Multiple Biomarkers in the Context of Conventional Risk Factors in Patients with Coronary Artery Disease","volume":"69","author":"Wang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ahj.2013.09.013","article-title":"Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study)","volume":"167","author":"Schopfer","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1373\/clinchem.2014.227116","article-title":"Biomarkers of cardiovascular stress and subclinical atherosclerosis in the community","volume":"60","author":"Gopal","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/1755-5922.12184","article-title":"Increased Serum Level of Growth Differentiation Factor 15 (GDF-15) is Associated with Coronary Artery Disease","volume":"34","author":"Wang","year":"2016","journal-title":"Cardiovasc. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/clc.20698","article-title":"Growth differentiation factor 15 and coronary collateral formation","volume":"33","author":"Sun","year":"2010","journal-title":"Clin. Cardiol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbalip.2009.02.015","article-title":"The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma","volume":"1791","author":"Tellis","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cca.2016.12.006","article-title":"Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis","volume":"465","author":"Li","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1038\/s41598-017-16464-5","article-title":"Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/ATVBAHA.112.249854","article-title":"Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation","volume":"32","author":"Edsfeldt","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"954","DOI":"10.5114\/aoms.2020.98195","article-title":"On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management","volume":"17","author":"Fras","year":"2021","journal-title":"Arch. Med. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e003407","DOI":"10.1161\/JAHA.116.003407","article-title":"Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk but Not a Useful Target for Treatment in Patients with Stable Coronary Heart Disease","volume":"5","author":"Wallentin","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Cai, A., Li, G., Chen, J., Li, X., Li, L., and Zhou, Y. (2015). Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: A cross-sectional study of Chinese population. BMC Cardiovasc. Disord., 15.","DOI":"10.1186\/s12872-015-0001-9"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1111\/jcmm.13803","article-title":"Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study","volume":"22","author":"Liu","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"931931","DOI":"10.3389\/fphys.2022.931931","article-title":"Low-density lipoprotein particles in atherosclerosis","volume":"13","author":"Qiao","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2012.09.010","article-title":"Small dense LDL: An emerging risk factor for cardiovascular disease","volume":"414","author":"Hirayama","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0021-9150(96)05842-X","article-title":"Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans","volume":"124","author":"Anber","year":"1996","journal-title":"Atherosclerosis"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0167-5273(99)00107-2","article-title":"The role of small, dense low density lipoprotein (LDL): A new look","volume":"74","author":"Packard","year":"2000","journal-title":"Int. J. Cardiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0002-9343(00)00700-2","article-title":"Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins","volume":"110","author":"Tribble","year":"2001","journal-title":"Am. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","article-title":"Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study","volume":"34","author":"Hoogeveen","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.atherosclerosis.2009.11.040","article-title":"LDL and HDL subclasses in acute ischemic stroke: Prediction of risk and short-term mortality","volume":"210","author":"Zeljkovic","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-511X-10-21","article-title":"Small dense LDL particles\u2014A predictor of coronary artery disease evaluated by invasive and CT-based techniques: A case-control study","volume":"10","author":"Tilsted","year":"2011","journal-title":"Lipids Health Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.5551\/jat.60152","article-title":"Small Dense Low-Density Lipoprotein Cholesterol: A Residual Risk for Rapid Progression of Non-Culprit Coronary Lesion in Patients with Acute Coronary Syndrome","volume":"28","author":"Sekimoto","year":"2021","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12944-023-01819-x","article-title":"Estimated sdLDL-C for predicting high-risk coronary plaque features in psoriasis: A prospective observational study","volume":"22","author":"Sorokin","year":"2023","journal-title":"Lipids Health Dis."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/8\/1639\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:21:06Z","timestamp":1760127666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/8\/1639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":166,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["life13081639"],"URL":"https:\/\/doi.org\/10.3390\/life13081639","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}